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Abstract
Complement C1q is a soluble protein capable of initiating components of the classical path-
way in host defence system. In earlier qualitative studies, C1q has been implicated in the
pathogenesis of Erythema Nodosum Leprosum (ENL). However, little is known about the
role of this complement in ENL reaction. In the present study we described the protein level
of C1q production and its gene expression in the peripheral blood and skin biopsies in
patients with ENL reaction and lepromatous leprosy (LL) patient controls before and after
treatment. Thirty untreated patients with ENL reaction and 30 non-reactional LL patient con-
trols were recruited at ALERT Hospital, Ethiopia. Peripheral blood and skin biopsies were
obtained from each patient before and after treatment. The level of circulating C1q in the
plasma was determined by enzyme-linked immunosorbent assay. The mRNA expression of
the three C1q components, C1qA, C1qB, and C1qC in the peripheral blood and skin biopsies
was determined by qPCR. Circulating C1q in the peripheral blood of untreated ENL patients
was significantly decreased compared to LL patient controls. Untreated ENL patients had
increased C1q gene expression in the peripheral blood compared to LL controls. Similarly,
C1qA and C1qC gene expression were substantially increased in the skin biopsies of
untreated ENL patients compared to LL controls. However, after treatment none of these
genes show significant difference in both groups. In conclusion, while circulating C1q is
inversely correlated with active ENL reactions, its gene expression is directly correlated with
ENL. The decreased circulating C1q may suggest the utilization of C1q in immune-complex
formation in these patients. Therefore, C1q could be a potential diagnostic marker for active
ENL reactions as well as for monitoring ENL treatment.
Author summary
Erythema nodosum leprosum (ENL) is a painful inflammatory reaction which occurs in
patients with lepromatous and borderline lepromatous leprosy. The diagnosis of ENL is
mainly based on clinical signs and symptoms and there is no definitive laboratory diagno-
sis. The causes of ENL are not fully understood but immune-complexes and T-cells activa-
tion are among the main factors described by researches. Complement C1q is a protein
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which initiates the classical complement pathway to form antigen-antibody complex
(immune-complexes) which is normally removed before deposition. However, we do not
have clear information on the role of C1q in patients with ENL reaction. Therefore, we
investigated the production and gene expression of C1q in patients with ENL reaction
and in non-reactional LL patient controls before and after corticosteroid treatment of
ENL cases. We found that the amount of circulating C-q protein was significantly reduced
in untreated ENL patients compared to non-reactional LL patients and healthy controls.
On the other hand, the gene expression of C1q in peripheral blood and skin biopsies had
been considerably higher in untreated ENL patients compared to LL patients controls.
Both C1q protein and gene expression were not significantly different between the two
groups after corticosteroid treatment of ENL cases. The decreased C1q protein in
untreated ENL may indicate the consumption of C1q in immune-complex formation in
these patients and suggests that the involvement of immune-complex in the pathogenesis
of ENL. Hence, C1q could be used as a potential candidate marker for ENL diagnose in
the future.
Introduction
Leprosy is a chronic infectious disease caused by Mycobacterium leprae which infects mainly
skin and peripheral nerves [1]. The disease manifests with a spectrum of clinical pictures rang-
ing from the localized tuberculoid leprosy (TT) through borderline forms to the generalized
lepromatous leprosy (LL) of the Ridley-Jopling (RJ) classification [2]. Erythema nodosum
leprosum (ENL) is an immune-mediated inflammatory complication affecting about 50% of
patients with lepromatous leprosy (LL) and 10% of borderline lepromatous (BL) patients [3–
5]. ENL first occurs as acute but may pass in to a chronic phase or can be a recurrent [6]. It
involves multiple organs and manifests as systemic illness [7]. The occurrence of crops of ten-
der erythematous skin lesion is the clinical diagnostic of ENL [8]. Histologically, the infiltra-
tions of neutrophils throughout the dermis and subcutis is the defining characteristic of ENL
[9]. However, not all clinically confirmed ENL cases have neutrophilic infiltration in the
lesions.
ENL is mainly diagnosed clinically and if the facility is available supported by histological
findings. Nevertheless, no clinical or laboratory tests accurately predict who is most likely to
develop ENL reaction or when it might occur.
C1q is one of the several candidate markers proposed for ENL diagnosis in earlier studies
[10, 11]. However, little is known about the possible role of complement in ENL reaction.
Recently the complement system have been perceived as a central constituent of innate immu-
nity, defending the host against pathogens, coordinating various events during inflammation,
and bridging innate and adaptive immune responses [12]. Complement system not only pro-
tect the host against infection but also contribute to the amplification of inflammation if acti-
vated in excess or inappropriately controlled [13].
C1q is a 460-kDa protein made up of 18-subunit glycoprotein consisting of 3 subunits: A, B
and C which are coded by C1qA, C1qB and C1qC genes respectively. It has been shown that
C1q is assembled in a 1:1:1 ratio from these three different subunits. The three human C1q
genes are closely located on chromosome 1 and arranged C1qA-C1qC-C1qB orders [14]. It is
believed that C1q is mainly produced by macrophages [15]. It has been reported that IFN-γ
and IL-6 promote C1q production by macrophages while IL-1 inhibits its production by mac-
rophages [16]. C1q initiate the classical complement pathway. However, recently it has been
C1q expression in ENL
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shown that C1q is also involved in non-complement activation such as modulating dendritic
cell maturation, pro-inflammatory cytokine production and T- and B-cell responses [17].
Increased C1q production in patients with active pulmonary tuberculosis (TB) compared
to latent TB has recently been reported indicating the potential use of C1q as biomarker to dis-
criminate between patients with active TB cases from latent TB [16]. C1q has also been impli-
cated in several immune-complex disorders such as acute glomerulonephritis [18] and acute
systemic lupus erythematosus (SLE) [19, 20] and rheumatoid arthritis [21].
Previous qualitative studies looked at C1q in the immunopathology of ENL and reported
that serum samples from leprosy with or without reaction confer similar results[10, 11, 22].
However, serum samples from leprosy with or without reaction showed positive test. A recent
microarrays study in the PBMCs of 3 ENL and 3 T1R patients has reported increased expres-
sion of the classic complement pathway particularly complement C1qA, B, C and the comple-
ment receptor C3AR1 and C5AR1 [23]. Increased fluorescent intensity of C1q in skin lesions
of these patients has also been reported in the same study. Therefore, the association of C1q
with the pathophysiology of ENL need to be explored in large number of ENL patient cohort.
In the present study, the circulating C1q in the peripheral blood of patients with ENL and LL
controls before and after prednisolone treatment was quantified using a special C1q-ELISA.
The gene expression of C1q (C1qA, C1qB and C1qC) was quantified in peripheral blood and
skin biopsies of these patients by quantitative polymerase chain reaction (RT-qPCR) before
and after prednisolone treatment of ENL patients.
Materials and methods
Ethical statement
Informed written consent for blood and skin biopsies were obtained from patients following
approval of the study by the Institutional Ethical Committee of London School of Hygiene and
Tropical Medicine, UK, (#6391), AHRI/ALERT Ethics Review Committee, Ethiopia (P032/12)
and the National Research Ethics Review Committee, Ethiopia (#310/450/06). Children under
18 years old and minor or vulnerable groups have been excluded from the study. All patient
data analyzed and reported anonymously.
Patient recruitment
We recruited 30 untreated patients with ENL reaction and 30 matched non reactional LL
patient controls. All patients recruited into this study were attending the ALERT Hospital,
Addis Ababa, Ethiopia. The patients were classified on the leprosy spectrum based on the Rid-
ley-Jopling (RJ) classification schemes [2]. ENL was clinically diagnosed when a patient with BL
or LL leprosy had painful crops of tender cutaneous erythematous skin lesions [4]. New ENL
was defined as the occurrence of ENL for the first time in a patient with LL or BL. Lepromatous
leprosy was clinically diagnosed when a patient had widely disseminated nodular lesions with
ill-defined borders and BI above 2 [24]. Patients with ENL were treated according to the World
Health Organization (WHO) treatment guideline with steroids that initially consisted of 40mg
oral prednisolone daily and the dose was tapered by 5mg every fortnight for 24 weeks. All
patients were received WHO-recommended leprosy multidrug treatment (MDT). We also
included 15 apparently healthy volunteers and used for C1q ELISA result comparison only.
Blood and skin biopsy samples
Ten micro-litter of venous blood was collected into sterile BD heparinised vacutainer tubes
(BD, Franklin, Lakes, NJ, USA) before and after prednisolone treatment of ENL cases on week
C1q expression in ENL
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24 from each patient and healthy controls. Plasma was separated and used for ELISA. In addi-
tion, 2mL of blood was collected into PAXgene Blood RNA Tubes (PreAnalytix, GmbH, Swit-
zerland) before, and after prednisolone treatment for mRNA isolation and stored at -80˚C.
Six-mm punch biopsy was taken from each patient before and after prednisolone treatment
into a to a Nunc tube containing 1mL RNAlater solution (Thermo-Fisher Scientific) and was
kept at -20˚C for 48 hours and then transferred to -80 oC freezer. The ENL and LL lesions for
biopsy sample were identified and marked by a dermatologist and then biopsy samples were
taken from the marked area by trained research nurses under supervision. For ethical reason
we didn’t collect biopsy samples from healthy controls.
Cytokine measurement by ELISA
For quantitative detection of human C1q in the plasma samples of patients with ENL, non
reactional LL and healthy controls, we used human C1q platinum ELISA (ready-to-use sand-
wich ELISA) with a sensitivity of 0.08ng/mL purchased from eBioscience (Affymetrix,
eBioscience, UK). The procedure is briefly described as follow as: The microwell plate coated
with monoclonal antibody to human C1q was aspirated and washed twice with wash buffer.
Then 100μl of serially diluted C1q standard was pipetted to the first two columns of the micro-
well strips. To the remaining strips pre-diluted to 1:1000 plasma samples (100μl/well) were
added and to the last two wells a blank (assay buffer) was added as a negative control. The
plate was sealed and incubated at 22˚C for 2hrs on a microplate shaker set at 400 revolutions
per minute (rpm). After 2 hours incubation, the plate was washed 6 times with wash buffer
and tapped on the absorbent pad. To each well, 100μl of biotin-conjugated anti-human C1q
antibody was added and incubated at 22˚C for 1hr on a microplate shaker set at 400rpm. Then
the microplate was washed as described above and followed by the addition of 100μl Streptavi-
din-HRP to all wells. The plate was sealed and incubated at 22˚C for 1hr on a microplate
shaker as described. After six washes 100μl of TMB substrate solution was added to all wells
and incubated at 22˚C for 30 minutes in the dark. The colour development on the plate was
monitored and the substrate reaction was stopped by pipetting 100μl of stop solution (1N
H3PO4). The optical density (OD) at 450nm was measured using an ELISA plate reader
(Microplate reader; Bio-Rad, Richmond, CA). A curve fit was applied to the standard curve
according to the manufacturer’s manual using Microplate Manager 6 Software (Bio-Rad, Rich-
mond, CA) and the unknown concentration of C1q in each sample was extrapolated from
these standard curves.
RNA isolation and reverse transcription
Isolation of RNA from peripheral blood and skin biopsies stored in RNAlater (Ambion, Aus-
tin, Texas) was performed using PAXgene Blood RNA Kit and RNeasy Fibrous Tissue Kit
(QIAGEN Crawley, West Sussex, United Kingdom) respectively according to the manufactur-
er’s protocol. DNase I (QIAGEN) was included for all RNA preparations for DNA digestion.
RNA yield was determined using a NanoDrop 2000, spectrophotometer (Thermo Scientific,
Epsom, UK) and integrity was checked by agarose gel electrophoresis. For all samples Comple-
mentary DNA (cDNA was synthesized on the same day to avoid the risk of RNA degrades dur-
ing storage. cDNA was synthesised from RNA (200 ng/reaction mixture) using High Capacity
cDNA Reverse Transcriptase Kit (AB Applied Biosystems, UK). Reactions were incubated in
an ABI9700 Programmable Thermal Cycler (Applied Biosystems, Foster City, California) for
10 minutes at 25˚C followed by 120 minutes at 37˚C and 5 minutes at 85˚C and then cooling
to 4˚C.
C1q expression in ENL
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Primers and quantitative polymerase chain reaction (qPCR)
Primers between 20–24 nucleotides in length were designed across intron/exon boundaries on
mRNA sequence obtained from the Nation Centre for Biotechnology Information database
(NCBI) to give a product between 100-500bp. All primer sequences were blasted on the NCBI
data bank to confirm their specificity. Custom synthesis of oligonucleotide primers was per-
formed by Sigma-life science and provided in desalted form. The nucleotide sequences of the
forward and reverse primers, respectively, used in this study were as follows: for C1-qA, 5’-
ATGGTGACCGAGGACTTGTG-3’ and 5’-GTCCTTGATGTTTCCTGG GC-3’; for C1-qB,
5’-CAGGTTGAAATCAGCATTGCC-3’ and 5’-CTGTGTCAGACGCCT CCTTTC-3’; for
C1-qC, 5’-AAGGATGGGTACGACGGACTG-3’ and 5’- TTTCTGCTTGTA TCTGCCCTC-
3’ and for human acidic ribosomal protein (HuPO) house-keeping gene: 5’-G GACTCGTT
TGTACCCGTTG-3’ and 5’-GGACTCGTTTGTA CC CG TTG-3’.
Real-time quantitative PCR for all genes was performed on the Rotor-Gene 3000 program-
mable thermal cycler (Corbett Life Science, Qiagen, Crawley, UK) using Roter-gene SYBR
Green PCR Kit (Qiagen, Crawley, UK). The Rotor-Gene conditions were set as follows: Initial
activation step (polymerase activation) was achieved by incubating at 95˚C for 15 minutes, 40
cycles of denaturation at 95˚C for 5 seconds, annealing at 60˚C for 10 seconds, extension at
72˚C for 20 seconds and fluorescence acquisition for 5 seconds at 72˚C. The primer-dimer for-
mation was checked by melting curve analysis. Melting point data were obtained by increasing
the temperature from 50˚C to 99˚C by 1˚C on each step. The interval between increases in
temperature was 30 seconds for the first step and then 5 seconds for subsequent steps. An
assay control was included from mRNA extraction to the amplification steps. For mRNA
extraction, one assay control per batch was used. The assay control included all buffers except
the sample and was processed under identical conditions with the samples. The same assay
control was used during cDNA synthesis and real-time quantitative PCR.
Calculating the relative gene expression
The relative gene expression (fold change) was analyzed by using the 2-ΔΔ CT method (Cikos
et al., 2007). The difference in threshold number for the amplification of the target gene (ΔCT)
was obtained by subtracting the CT of the target gene from the CT of the control gene. To com-
pare the target gene expression in patients with ENL and LL controls, ΔΔCT was obtained by
subtracting the ΔCT of LL patient control from the ΔCT of the patient with ENL. Then, the fold
change (FC) was obtained by using the formula FC = 2-ΔΔ CT. Similarly, for the comparison of
the relative target gene expression within ENL group before and after treatment, ΔΔCT was
obtained by ΔCT (after) minus ΔCT (before). Then the fold change for the target gene expres-
sion in untreated ENL was given by 2-ΔΔ CT.
Stastical methods
ELISA data. The optical density of each sample for each cytokine was obtained by the
ELISA reader. The OD was converted to concentration (pg/mL) by microplate manager 6.
Unpaired t-test was used to compare the relative concentration of the cytokines production in
patients with ENL and LL controls. For comparing the cytokine concentration in patients with
ENL before and after treatment, paired t-test was used. Results are presented as mean ± stan-
dard error of the mean (SE) with P-values with a cut off 0.05. SE was chosen since the primary
objective of the study was to measure how the mean of the sample is related to the mean of the
underlying population. SE takes standard deviation and sample size into account.
Real-time quantitative PCR. for the mRNA gene expression of target genes, the relative
threshold cycle value (CT) comparison method was used. The fold change of each target gene
C1q expression in ENL
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was used for statistical analysis. Unpaired t-test was used to compare the fold change of each
target gene for patients with ENL compared to LL patient controls. To compare the expression
level of the desired gene in patients with ENL before and after treatment, paired t-test was
used.
Results
Patient clinical background
Thirty patients with ENL reaction and 30 LL patient controls without ENL reaction were
recruited between December 2013 and October 2015. The male to female ratio was 2:1 with a
median age of 27.5 [range: 18–56] years in patients with ENL and 3:1 with a median age of
25.0 [range: 18–60] years in patients with non-reactional LL controls. All ENL patients were
untreated with corticosteroid before recruitment. At time of recruitment, 20 ENL patients
were previously untreated with MDT, 21 were on MDT and 5 were completed MDT treat-
ment. Twenty non-reactional LL patients were about to start MDT, 7 were on MDT and 4
were completed MDT at recruitment. From 15 apparently healthy controls, 9 were male and 6
were female with median age of 26.5 [range: 20–57] years.
Circulating C1q production is decreased in the peripheral blood of
untreated patients with ENL reactions
Patients with ENL reactions had significantly lower circulating C1q (11698pg/mL ± 618.3)
compared to LL patient controls (21059pg/mL ± 2382.0) and health controls (18448pg/
mL ± 1161) before treatment (P 0.0001) (Fig 1A). However, the amount of circulating C1q
considerably increased in ENL patient to 22287pg/mL ± 2154 after treatment while it was only
slightly increased to 23721pg/mL ± 1886 in LL patient controls. Circulating C1-q production
was similar in patients with ENL and LL controls after treatment (Fig 1B). Similar, C1q pro-
duction was similar in patients with ENL reactions (after treatment) and healthy controls (P
0.0001). Although, C1q production was slightly higher (but not significantly different) in LL
patients controls compared to health controls before and after treatment, (Fig 1B).
Comparison within patients with ENL reactions before and after treatment has shown that
circulating C1q production in the peripheral blood of ENL patients was considerably increased
after prednisolone treatment and the difference significantly different (P 0.0001) (Fig 1C).
This indicates that patients with ENL reactions do not have C1q genetic defect since the level
of C1q production has increased after the ENL reactions subside.
Increased C1q gene expression in untreated patients with ENL reactions
We quantified the mRNA gene expressions for the three genes (C1qA, C1qB, C1qC) in the
blood and skin biopsies obtained from patients with ENL and LL controls before and after
treatment.
The gene expression for C1qA (FC = 2.56), C1qB (FC = 2.63) and C1qC (FC = 4.55) in the
peripheral blood of untreated patients with ENL reaction were significantly increased com-
pared to the corresponding non-reactional LL patient controls (P 0.05). In skin biopsies,
increased expression of C1qA (FC = 6.45) and C1qC (FC = 7.46) was associated with untreated
active patients with ENL reactions compared to LL patient controls (P 0.05). However,
unlike in the peripheral blood, the gene expression for C1qB in untreated patients with ENL
was not statistically significantly different compared to LL patient controls. None of these
genes show significant difference after treatment in both groups (Table 1).
C1q expression in ENL
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C1q gene expression in the peripheral blood and skin biopsies were also compared within
ENL group before and after prednisolone treatment. The gene expression for all the three
genes in the peripheral blood was not statistically significantly different before and after treat-
ment within the ENL group. The gene expression in the skin biopsies for C1qA and C1qB did
not change before and after treatment within ENL group. Interestingly, the C1qC gene expres-
sion in the skin biopsies remarkably decreased (FC = 0.13) after treatment within ENL group
(P< 0.0001) (Table 2).
Fig 1. Circulating C1q production in patients with ENL, LL controls and healthy controls. (A): Before treatment, (B): after
treatment, (C): within ENL groups before and after treatment.  P< 0.0001. Error bars show mean ± Standard error of the mean.
https://doi.org/10.1371/journal.pntd.0006321.g001
Table 1. C1q gene expression in peripheral blood and skin biopsy samples from patients with ENL and LL controls before and after treatment.
Sample gene of interest Before treatment After treatment
ΔΔCT FC P Value ΔΔCT FC P -Value
Blood C1q-A -1.36 2.56 0.0069  -0.54 1.45 0.3928
C1-B -1.39 2.63 0.0402  -0.80 1.74 0.3576
C1q-C -2.19 4.55 0.0018  -0.58 1.49 0.4044
Tissue C1q-A -2.69 6.45 0.0231 0.37 0.78 0.7661
C1-B 0.56 0.68 0.3713 0.89 0.54 0.2072
C1q-C -2.90 7.46 < 0.0001  1.13 0.46 0.0737
Statistical test: unpaired t-test. ΔΔCT = delta delta CT; FC = fold change
statistically significant at α = 0.05.
https://doi.org/10.1371/journal.pntd.0006321.t001
C1q expression in ENL
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Discussion
The amount of circulating C1q in the plasma of patients with ENL and LL was quantified
using a C1q ELISA. The gene expression of C1q was also quantified in blood and skin biopsy
samples of these patients before and after treatment. Patients with ENL had significantly lower
circulating concentrations of C1q than LL controls before treatment. However, after treat-
ment, the amount of circulating C1q was not significantly different in both groups. This is the
first work to determine circulating C1q production using ELISA in leprosy patients in leprosy
patients with and without ENL. Therefore, comparison with previous studies would not have
been possible. one earlier qualitative study had reported that lower C1q binding activity in the
sera of untreated ENL patients compared to treated ENL patients[25].
The decreased frequency of circulating C1q in the sera of untreated patients with ENL com-
pared to healthy controls as well as non reactional LL patient controls could be due to its utili-
sation by the antigen-antibody complex formation in ENL reaction. Similarly, a decreased
serum complement C1q levels have been observed in other immune complex disorders such
as acute glomerulonephritis (Lange et al., 1960, Lewis et al., 1971, Ohi and Tamano, 2001) and
acute systemic lupus erythematosus (SLE) (Baatrup et al., 1984, Grevink et al., 2005). However,
since the pathophysiology of autoimmune disorders and infectious diseases like ENL reactions
are different, further study is required.
The gene expression level of C1q A, B and C in the blood and C1q A, and C in the skin biop-
sies from patients with ENL reactions were significantly higher than in LL controls before
treatment. However, after treatment, none of these genes were found to be significantly differ-
ent between the two groups. It is interesting to note that while the amount of circulating C1q
protein is decreased in active ENL, its gene expression is increased in untreated ENL patients
compared to the corresponding LL patient controls. This phenomenon may be explained by
the utilization of C1q in immune-complex formation in active ENL patients. Although the ini-
tiation of ENL is not precisely known, several studies have reported the involvement of
immune-complexes in the pathophysiology of ENL reaction. Immune-complexes activate the
classical complement pathway that opsonise or coat antigen-antibody complexes with comple-
ment molecules which facilitates the clearance of immune-complexes by the macrophages
[26]. Hence, by maintaining immune-complexes in solution, the complements allow clearance
of the complexes from their site of formation, minimizing local inflammatory consequences
[26]. However, in the event of immune-complexes deposition complements are consumed
until [27].
In the comparison within ENL group, it has been found that C1qC gene expression was sig-
nificantly increased in the skin biopsies of untreated ENL and subsequently decreased after
Table 2. C1q gene expression in peripheral blood and skin biopsies samples from patients with ENL reactions before and after treatment.
Samples Gene of interest ΔΔCT FC P-value Gene expression after treatment
Blood C1q-A 0.66 0.63 0.1116 No change
C1-B 0.64 0.64 0.3309 No change
C1q-C 0.43 0.74 0.4178 No change
Tissue C1q-A -0.3 1.23 0.0839 No change
C1-B 0.11 0.92 0.9302 No change
C1q-C 2.93 0.13 < 0.0001  Decreased
Statistical test: paired t-test. ΔΔCT = delta delta CT; Fc- Fold change
statistically significant at α = 0.05.
https://doi.org/10.1371/journal.pntd.0006321.t002
C1q expression in ENL
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ENL Treatment. The increased C1qC gene expiration in untreated active ENL may be associ-
ated with the immune activation in ENL reactions. Previously we have shown that increased
T-cell activation in untreated active ENL patient compared to non-reactional LL controls [27].
It has also been reported that the inflammatory cytokines such as IFN-γ and IL-6 increase C1q
production by macrophages [28]. Several studies indicated that C1q can modulate dendritic
cell maturation, pro-inflammatory cytokine production, and T- and B-cell responses in addi-
tion to its classical function to initiate complement activation [29–31]. Recently, increased cir-
culating C1q and C1qC gene expression in patients with active tuberculosis compared to
healthy controls and individuals with latent TB infection has been reported [16] indicating its
potential use as a biomarker to discriminate active TB from latent TB cases. Therefore, in the
same scenario, C1qC gene expression could be used as potential diagnostic marker for ENL,
which necessities further investigation particularly in the lesions.
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